Session Type: ePosters
Session Title: ePosters
Authors(s): A. Liapikou (1, 2), V. Kossyvaki (3), J. Skiadas (3), D. Menegas (3), C. Mendez (4), R. Beavon (5), E. Begier (6), B. Gessner (6), H. Milionis (7), V. Tsimihodimos (8), A. Konstantinidis (9), G. Baxevanos (10), T. Argiriadou (11), C. Terrovitou (12), M. Toumbis (1)
Authors Affiliations(s): (1) Hellenic Thoracic Society, Greece, (2) 6th Respiratory Medicine Department, Sotiria Hospital, Greece, (3) Pfizer Greece, Greece, (4) Pfizer Spain, Spain, (5) MDSCA Global Vaccines, Pfizer Ltd., United Kingdom, (6) Global Vaccines, Pfizer Inc., United States, (7) 1st Internal Medicine Department, University Hospital of Ioannina, Greece, (8) 2nd Internal Medicine Department, University Hospital of Ioannina, Greece, (9) Department of Respiratory Medicine, University Hospital of Ioannina, Greece, (10) Internal Medicine Department, General Hospital of Ioannina "G. Hatzikosta", Greece, (11) 1st Respiratory Medicine Department, General Hospital of Kavala, Greece, (12) 2nd Respiratory Medicine Department, General Hospital of Kavala, Greece
Third Party Affiliation: The EGNATIA Study Group
Background:
Pneumococcal conjugate vaccines (PCVs) have changed the epidemiology of pneumococcal disease worldwide. In Greece, PCVs have been included in the infant National Immunization Program since 2006 (PCV13 since 2010). Since 2015, PCV13 has been recommended for younger adults (18–64 years) with at-risk and high-risk conditions and older adults age ≥65 years sequentially before 23-valent pneumococcal polysaccharide vaccine (PPV23). As of 2019, >30% of Greek adults aged ≥65 years are estimated to have ever received PCV13 versus <10% in adults <65 years. Our study assessed pneumococcal serotype distribution among hospitalized community-acquired pneumonia (CAP) and pneumococcal CAP (pCAP) from November 2017 to April 2019 among adults with and without comorbidities.
Methods:EGNATIA is a prospective, population-based study of adults ≥19 years old hospitalized with clinical and radiographically confirmed CAP in the Ioannina and Kavala regions of Greece. Pneumococcus was identified using serotype-specific urinary antigen detection assays (UAD 1/2); BinaxNow® and conventional cultures. UAD1 detects serotypes in PCV13, UAD2 detects additional serotypes in PCV20 (Pfizer’s vaccine candidate) and PPV23.
Results:
The study included 482 hospitalized CAP patients. 56.4% were male, and mean age was 70.5 years. 79.5% of patients with CAP had ≥1 pre-existing risk factor, most frequently diabetes mellitus (22.8%), coronary artery disease (17.6%), and chronic obstructive pulmonary disease (14.7%). 65.3% of patients fell into the highest Pneumonia Severity Index Risk Classes (IV-V). 1.9% of CAP patients aged 19–64 years and 7.6% of patients ≥65 years had been ever vaccinated with PCV13 based on electronic prescribing system data. Pneumococcus was identified in 65 patients (13.5%). Pneumococcal serotypes – identified mainly through UAD1/2 – are presented by PCV formulation by age and risk groups (Table 1).
Conclusions:Despite a well-established pediatric PCV13 vaccination program, this adult population hospitalized with predominantly severe CAP had persistent PCV13 serotype disease, mainly in those <65 years old and those without a specific risk condition targeted for immunization. Increased PCV13 uptake among adults, and, if licensed, PCV15 and PCV20 vaccines under development could reduce CAP cases further.
Keyword(s): pneumococcal serotypes, community-acquired pneumonia in adults, GreeceCOI Stock Options: Yes
COI Other: EGNATIA study is a Clinical Research Collaboration between Pfizer and Hellenic Thoracic Society
Session Type: ePosters
Session Title: ePosters
Authors(s): A. Liapikou (1, 2), V. Kossyvaki (3), J. Skiadas (3), D. Menegas (3), C. Mendez (4), R. Beavon (5), E. Begier (6), B. Gessner (6), H. Milionis (7), V. Tsimihodimos (8), A. Konstantinidis (9), G. Baxevanos (10), T. Argiriadou (11), C. Terrovitou (12), M. Toumbis (1)
Authors Affiliations(s): (1) Hellenic Thoracic Society, Greece, (2) 6th Respiratory Medicine Department, Sotiria Hospital, Greece, (3) Pfizer Greece, Greece, (4) Pfizer Spain, Spain, (5) MDSCA Global Vaccines, Pfizer Ltd., United Kingdom, (6) Global Vaccines, Pfizer Inc., United States, (7) 1st Internal Medicine Department, University Hospital of Ioannina, Greece, (8) 2nd Internal Medicine Department, University Hospital of Ioannina, Greece, (9) Department of Respiratory Medicine, University Hospital of Ioannina, Greece, (10) Internal Medicine Department, General Hospital of Ioannina "G. Hatzikosta", Greece, (11) 1st Respiratory Medicine Department, General Hospital of Kavala, Greece, (12) 2nd Respiratory Medicine Department, General Hospital of Kavala, Greece
Third Party Affiliation: The EGNATIA Study Group
Background:
Pneumococcal conjugate vaccines (PCVs) have changed the epidemiology of pneumococcal disease worldwide. In Greece, PCVs have been included in the infant National Immunization Program since 2006 (PCV13 since 2010). Since 2015, PCV13 has been recommended for younger adults (18–64 years) with at-risk and high-risk conditions and older adults age ≥65 years sequentially before 23-valent pneumococcal polysaccharide vaccine (PPV23). As of 2019, >30% of Greek adults aged ≥65 years are estimated to have ever received PCV13 versus <10% in adults <65 years. Our study assessed pneumococcal serotype distribution among hospitalized community-acquired pneumonia (CAP) and pneumococcal CAP (pCAP) from November 2017 to April 2019 among adults with and without comorbidities.
Methods:EGNATIA is a prospective, population-based study of adults ≥19 years old hospitalized with clinical and radiographically confirmed CAP in the Ioannina and Kavala regions of Greece. Pneumococcus was identified using serotype-specific urinary antigen detection assays (UAD 1/2); BinaxNow® and conventional cultures. UAD1 detects serotypes in PCV13, UAD2 detects additional serotypes in PCV20 (Pfizer’s vaccine candidate) and PPV23.
Results:
The study included 482 hospitalized CAP patients. 56.4% were male, and mean age was 70.5 years. 79.5% of patients with CAP had ≥1 pre-existing risk factor, most frequently diabetes mellitus (22.8%), coronary artery disease (17.6%), and chronic obstructive pulmonary disease (14.7%). 65.3% of patients fell into the highest Pneumonia Severity Index Risk Classes (IV-V). 1.9% of CAP patients aged 19–64 years and 7.6% of patients ≥65 years had been ever vaccinated with PCV13 based on electronic prescribing system data. Pneumococcus was identified in 65 patients (13.5%). Pneumococcal serotypes – identified mainly through UAD1/2 – are presented by PCV formulation by age and risk groups (Table 1).
Conclusions:Despite a well-established pediatric PCV13 vaccination program, this adult population hospitalized with predominantly severe CAP had persistent PCV13 serotype disease, mainly in those <65 years old and those without a specific risk condition targeted for immunization. Increased PCV13 uptake among adults, and, if licensed, PCV15 and PCV20 vaccines under development could reduce CAP cases further.
Keyword(s): pneumococcal serotypes, community-acquired pneumonia in adults, GreeceCOI Stock Options: Yes
COI Other: EGNATIA study is a Clinical Research Collaboration between Pfizer and Hellenic Thoracic Society
Session Type: ePosters
Session Title: ePosters
Authors(s): A. Liapikou (1, 2), V. Kossyvaki (3), J. Skiadas (3), D. Menegas (3), C. Mendez (4), R. Beavon (5), E. Begier (6), B. Gessner (6), H. Milionis (7), V. Tsimihodimos (8), A. Konstantinidis (9), G. Baxevanos (10), T. Argiriadou (11), C. Terrovitou (12), M. Toumbis (1)
Authors Affiliations(s): (1) Hellenic Thoracic Society, Greece, (2) 6th Respiratory Medicine Department, Sotiria Hospital, Greece, (3) Pfizer Greece, Greece, (4) Pfizer Spain, Spain, (5) MDSCA Global Vaccines, Pfizer Ltd., United Kingdom, (6) Global Vaccines, Pfizer Inc., United States, (7) 1st Internal Medicine Department, University Hospital of Ioannina, Greece, (8) 2nd Internal Medicine Department, University Hospital of Ioannina, Greece, (9) Department of Respiratory Medicine, University Hospital of Ioannina, Greece, (10) Internal Medicine Department, General Hospital of Ioannina "G. Hatzikosta", Greece, (11) 1st Respiratory Medicine Department, General Hospital of Kavala, Greece, (12) 2nd Respiratory Medicine Department, General Hospital of Kavala, Greece
Third Party Affiliation: The EGNATIA Study Group
Background:
Pneumococcal conjugate vaccines (PCVs) have changed the epidemiology of pneumococcal disease worldwide. In Greece, PCVs have been included in the infant National Immunization Program since 2006 (PCV13 since 2010). Since 2015, PCV13 has been recommended for younger adults (18–64 years) with at-risk and high-risk conditions and older adults age ≥65 years sequentially before 23-valent pneumococcal polysaccharide vaccine (PPV23). As of 2019, >30% of Greek adults aged ≥65 years are estimated to have ever received PCV13 versus <10% in adults <65 years. Our study assessed pneumococcal serotype distribution among hospitalized community-acquired pneumonia (CAP) and pneumococcal CAP (pCAP) from November 2017 to April 2019 among adults with and without comorbidities.
Methods:EGNATIA is a prospective, population-based study of adults ≥19 years old hospitalized with clinical and radiographically confirmed CAP in the Ioannina and Kavala regions of Greece. Pneumococcus was identified using serotype-specific urinary antigen detection assays (UAD 1/2); BinaxNow® and conventional cultures. UAD1 detects serotypes in PCV13, UAD2 detects additional serotypes in PCV20 (Pfizer’s vaccine candidate) and PPV23.
Results:
The study included 482 hospitalized CAP patients. 56.4% were male, and mean age was 70.5 years. 79.5% of patients with CAP had ≥1 pre-existing risk factor, most frequently diabetes mellitus (22.8%), coronary artery disease (17.6%), and chronic obstructive pulmonary disease (14.7%). 65.3% of patients fell into the highest Pneumonia Severity Index Risk Classes (IV-V). 1.9% of CAP patients aged 19–64 years and 7.6% of patients ≥65 years had been ever vaccinated with PCV13 based on electronic prescribing system data. Pneumococcus was identified in 65 patients (13.5%). Pneumococcal serotypes – identified mainly through UAD1/2 – are presented by PCV formulation by age and risk groups (Table 1).
Conclusions:Despite a well-established pediatric PCV13 vaccination program, this adult population hospitalized with predominantly severe CAP had persistent PCV13 serotype disease, mainly in those <65 years old and those without a specific risk condition targeted for immunization. Increased PCV13 uptake among adults, and, if licensed, PCV15 and PCV20 vaccines under development could reduce CAP cases further.
Keyword(s): pneumococcal serotypes, community-acquired pneumonia in adults, GreeceCOI Stock Options: Yes
COI Other: EGNATIA study is a Clinical Research Collaboration between Pfizer and Hellenic Thoracic Society
Session Type: ePosters
Session Title: ePosters
Authors(s): A. Liapikou (1, 2), V. Kossyvaki (3), J. Skiadas (3), D. Menegas (3), C. Mendez (4), R. Beavon (5), E. Begier (6), B. Gessner (6), H. Milionis (7), V. Tsimihodimos (8), A. Konstantinidis (9), G. Baxevanos (10), T. Argiriadou (11), C. Terrovitou (12), M. Toumbis (1)
Authors Affiliations(s): (1) Hellenic Thoracic Society, Greece, (2) 6th Respiratory Medicine Department, Sotiria Hospital, Greece, (3) Pfizer Greece, Greece, (4) Pfizer Spain, Spain, (5) MDSCA Global Vaccines, Pfizer Ltd., United Kingdom, (6) Global Vaccines, Pfizer Inc., United States, (7) 1st Internal Medicine Department, University Hospital of Ioannina, Greece, (8) 2nd Internal Medicine Department, University Hospital of Ioannina, Greece, (9) Department of Respiratory Medicine, University Hospital of Ioannina, Greece, (10) Internal Medicine Department, General Hospital of Ioannina "G. Hatzikosta", Greece, (11) 1st Respiratory Medicine Department, General Hospital of Kavala, Greece, (12) 2nd Respiratory Medicine Department, General Hospital of Kavala, Greece
Third Party Affiliation: The EGNATIA Study Group
Background:
Pneumococcal conjugate vaccines (PCVs) have changed the epidemiology of pneumococcal disease worldwide. In Greece, PCVs have been included in the infant National Immunization Program since 2006 (PCV13 since 2010). Since 2015, PCV13 has been recommended for younger adults (18–64 years) with at-risk and high-risk conditions and older adults age ≥65 years sequentially before 23-valent pneumococcal polysaccharide vaccine (PPV23). As of 2019, >30% of Greek adults aged ≥65 years are estimated to have ever received PCV13 versus <10% in adults <65 years. Our study assessed pneumococcal serotype distribution among hospitalized community-acquired pneumonia (CAP) and pneumococcal CAP (pCAP) from November 2017 to April 2019 among adults with and without comorbidities.
Methods:EGNATIA is a prospective, population-based study of adults ≥19 years old hospitalized with clinical and radiographically confirmed CAP in the Ioannina and Kavala regions of Greece. Pneumococcus was identified using serotype-specific urinary antigen detection assays (UAD 1/2); BinaxNow® and conventional cultures. UAD1 detects serotypes in PCV13, UAD2 detects additional serotypes in PCV20 (Pfizer’s vaccine candidate) and PPV23.
Results:
The study included 482 hospitalized CAP patients. 56.4% were male, and mean age was 70.5 years. 79.5% of patients with CAP had ≥1 pre-existing risk factor, most frequently diabetes mellitus (22.8%), coronary artery disease (17.6%), and chronic obstructive pulmonary disease (14.7%). 65.3% of patients fell into the highest Pneumonia Severity Index Risk Classes (IV-V). 1.9% of CAP patients aged 19–64 years and 7.6% of patients ≥65 years had been ever vaccinated with PCV13 based on electronic prescribing system data. Pneumococcus was identified in 65 patients (13.5%). Pneumococcal serotypes – identified mainly through UAD1/2 – are presented by PCV formulation by age and risk groups (Table 1).
Conclusions:Despite a well-established pediatric PCV13 vaccination program, this adult population hospitalized with predominantly severe CAP had persistent PCV13 serotype disease, mainly in those <65 years old and those without a specific risk condition targeted for immunization. Increased PCV13 uptake among adults, and, if licensed, PCV15 and PCV20 vaccines under development could reduce CAP cases further.
Keyword(s): pneumococcal serotypes, community-acquired pneumonia in adults, GreeceCOI Stock Options: Yes
COI Other: EGNATIA study is a Clinical Research Collaboration between Pfizer and Hellenic Thoracic Society